Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

DualityBio and BioNTech to Begin Phase III US Trial of ADC for Breast Cancer

publication date: Sep 1, 2023

Duality Biologics (Suzhou), together with its partner BioNTech, will start a US Phase III trial of DB-1303, a topoisomerase-1 inhibitor-based ADC directed against HER2 breast cancer. Earlier this year, Duality out-licensed global rights (ex-China) for DB-1303 to BioNTech in a $1.5 billion deal. DB-1303 targets breast cancer patients with low levels of HER2, a level previously considered HER2 negative. The candidate addresses the same indication as Enhertu, an AstraZeneca- Daiichi Sankyo drug that posted sales of $1.6 billion in 2022. However, the Duality-BioNTech candidate may demonstrate greater safety. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital